HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 12/20/2012 -- Amicus Therapeutics Inc. (NASDAQ:FOLD) tumbled after the company said a late-stage study of its lead drug candidate didn’t meet a primary goal, dashing hopes for near-term approval by regulators. Shares plunged 44% to $3.24 in premmarket trading.
Amicus Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.
Can FOLD Bounce Back? Find Out Here
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) is falling 16 percent to $8.94. The company announced that it has formally concluded its evaluation of strategic alternatives. The company also announced that it has appointed board member Paul Black as its president and chief executive.
Allscripts Healthcare Solutions, Inc. is a provider of clinical, financial, connectivity and information solutions and related professional services to hospitals, physicians and post-acute organizations. The Company provides a variety of integrated clinical software applications for hospitals, physician practices and post-acute organizations.
Can MDRX Recover After The Recent fall? Find Out Here
Bed Bath & Beyond (NASDAQ:BBBY) reported third quarter EPS of $1.03 after the bell Wednesday, up from $0.95 a year ago. Net sales were $2.702 billion, an increase of 15.3% from net sales of $2.344 billion last year. The consensus estimates were for EPS of $1.02 and revenues of $2.73 billion.
Bed Bath & Beyond Inc. is a chain of retail stores, operating under the names Bed Bath & Beyond (BBB), Christmas Tree Shops (CTS), Harmon and Harmon Face Values (Harmon) and buybuy BABY.
Can BBBY Jump Again? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)